KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for CRISPR Therapeutics AG (CRSP) over the last 7 years, with Q4 2025 value amounting to $53.7 million.

  • CRISPR Therapeutics AG's Other Operating Expenses rose 41553.23% to $53.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $309.7 million, marking a year-over-year increase of 15668.41%. This contributed to the annual value of $309.7 million for FY2025, which is 15668.41% up from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's Other Operating Expenses is $53.7 million, which was up 41553.23% from $57.1 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Other Operating Expenses ranged from a high of $141.4 million in Q2 2025 and a low of $6.8 million during Q4 2022
  • For the 5-year period, CRISPR Therapeutics AG's Other Operating Expenses averaged around $38.6 million, with its median value being $32.9 million (2021).
  • Per our database at Business Quant, CRISPR Therapeutics AG's Other Operating Expenses crashed by 7856.02% in 2022 and then surged by 41553.23% in 2025.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Other Operating Expenses stood at $31.8 million in 2021, then crashed by 78.56% to $6.8 million in 2022, then surged by 193.13% to $20.0 million in 2023, then plummeted by 47.92% to $10.4 million in 2024, then soared by 415.53% to $53.7 million in 2025.
  • Its Other Operating Expenses was $53.7 million in Q4 2025, compared to $57.1 million in Q3 2025 and $141.4 million in Q2 2025.